anticancer/stroke

FIELD OF INVENTION This invention relates to polyamine compounds and more particularly to tetraamine derivatives and their use as N-Methyl-D-Aspartate (NMDA) inhibitors for therapeutic treatment of neurodegenerative disorders, such as stroke, Alzheimer's disease, other neurodegenerative disorders,

This invention relates to a particular nitrone compound and its salts and their advantageous use as pharmaceutical nitrone free radical trapping agents. BACKGROUND INFORMATION Alpha-phenyl tert butyl nitrone ##STR1## or "PBN") was identified in the 1970s as a useful analytical reagent to be used in

BACKGROUND INFORMATION This invention relates to a particular nitrone compound and its salts and their advantageous use as pharmaceutical nitrone free radical trapping agents. BACKGROUND INFORMATION Alpha-phenyl tert butyl nitrone ##STR1## or "PBN") was identified in the 1970s as a useful analytical

FIELD OF THE INVENTION The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin

FIELD OF THE INVENTION The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin

SEQUENCE LISTING The present application is being filed along with a sequence listing in electronic format. The sequence listing is provided as a file entitled, "VLX0001-201-US 20131212 SequenceListing_ST25", created on Dec. 11, 2013 which is 90 Kb in size. The information in the electronic format

SEQUENCE LISTING The present application is being filed along with a sequence listing in electronic format. The sequence listing is provided as a file entitled, "VLX0001-201-US 20131212 SequenceListing_ST25", created on Dec. 11, 2013 which is 90 Kb in size. The information in the electronic format

SEQUENCE LISTING The present application is being filed along with a sequence listing in electronic format. The sequence listing is provided as a file entitled, "VLX0001-201-US 20131212 SequenceListing_ST25", created on Dec. 11, 2013 which is 90 Kb in size. The information in the electronic format

The present invention relates to antibodies that bind CD47 and their use in treating conditions and disorders, such as ischemia-reperfusion injury (IRI) and cancers, mediated by this receptor. CD47 is a cell surface receptor comprised of an extracellular IgV set domain, a 5 membrane spanning

INCORPORATION OF SEQUENCE LISTING The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled, "VLX0001-201CIP2 US_SequenceListing", created on Jun. 11, 2015, which is 168,755 bytes in size. The information in the

BACKGROUND The present disclosure relates to antibodies that bind CD47, including that of humans and other mammalian species, and their use in treating conditions and disorders, such as ischemia-reperfusion injury (IRI) and cancers, mediated by this receptor. CD47 is a cell surface receptor

BACKGROUND OF THE INVENTION The present invention relates to amide substituted indazoles which are inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), previously known as poly(ADP-ribose)synthase and poly(ADP-ribosyl)transferase. The compounds of the present invention are useful as

BACKGROUND OF THE INVENTION The present invention relates to pharmaceutically acceptable salts of an amide substituted indazole which are inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), previously known as poly(ADP-ribose)synthase and poly(ADP-ribosyl)transferase. The compounds of the

CROSS REFERENCE TO RELATED APPLICATIONS This application claims priority to currently pending U.S. Provisional Patent Application 60/882,330, entitled, "Stable Differentiation of Adult Stem Cells", filed Dec. 28, 2006, the contents of which are herein incorporated by reference. FIELD OF

The present invention relates to tricyclic derivatives which are inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), previously known as poly(ADP-ribose)synthase and poly(ADP-ribosyl)transferase. Compounds of the present invention are useful as mono-therapies in tumors with specific defects